Bassil Dahiyat, Xencor CEO
June 13, 2024 10:58 AM EDT
Deals
R&D

J&J re­turns bis­pe­cif­ic T cell en­gager to Xen­cor, re­duc­ing scope of part­ner­ship

Ayisha Sharma

News Reporter

John­son & John­son is hand­ing back a bis­pe­cif­ic T cell en­gager pro­gram to its part­ner Xen­cor, end­ing a sig­nif­i­cant piece of an agree­ment be­tween the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times